Oral anti-pseudomonal antibiotics for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Remmington, Tracey ^a   Jahnke, N ^b   Harkensee, C ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

Anti bacterial agents *therapeutic use ; Cystic fibrosis *complications; microbiology ; Pseudomonas aeruginosa; Pseudomonas infections *drug therapy ; Randomized controlled trials as topic

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZLOCILLIN; CEFTAZIDIME; CIPROFLOXACIN; CYCLOOXYGENASE 2 INHIBITOR; GENTAMICIN; MACROLIDE; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; TICARCILLIN; TOBRAMYCIN;

ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BODY WEIGHT; BREATHING EXERCISE; CHRONIC DISEASE; COCHRANE LIBRARY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LONG TERM CARE; LUNG FUNCTION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 40649098696     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005405.pub2     Document Type: Review

References (93)

1. Hodson 1987 {published data only} Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 1987:126.
2. Hodson ME, Roberts CM, Butland RJA, Batten JC. Ciprofloxacin compared with intravenous azlocillin and gentamicin in the treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF) [abstract]. Proceedings of the 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1-2 September 1986; Budapest. 1986:20.
3. *Hodson ME, Roberts CM, Butland RJA, Smith MJ. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1(8527):235- 7.
4. Jensen 1987 {published data only} Jensen T, Pedersen SS, Høiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987;6(6):618-22.
5. *Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987;20(4):585-94.
6. Pedersen SS, Jensen T, Hvidberg EF. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1987;20(4):575-83.
7. Richard 1997 {published and unpublished data} Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatric Infectious Disease Journal 1997;16(6):572-8.
8. Schaad 1997 {published and unpublished data} Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatric Infectious Disease Journal 1997;16(6):106-11.
9. Sheldon 1993 {published data only} Assoufi BK, Sheldon CD, Hodson ME. Double blind comparison of regular 3 monthly treatment with ciprofloxacin or placebo in cystic fibrosis patients who are chronically colonised with Pseudmonas aeruginosa [abstract]. Pediatric Pulmonology 1990;Suppl 5:204.
10. Assoufi BK, Sheldon CD, Hodson ME. Double blind comparison of regular three monthly treatment with ciprofloxacin or placebo in cystic fibrosis (CF) patients who are chronically colonised with Pseudmonas aeruginosa [abstract]. 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:32.
11. *Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respiratory Medicine 1993;87:587-93.
12. Wang 1988 {published data only} Wang CI, Inderlied CB, Armer C, Roldan MA, Osher AB. Comparison of the efficacy and safety of oral ciprofloxacin with that of i.v. tobramycin plus azlocillin and/or tobramycin plus ticarcillin in patients with cystic fibrosis [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)19.
13. Anstead 2001 Anstead M, Kuhn RJ, Halsey S, Doherty DE, D'Souza N, Kanga JF. Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A565.
14. Bosso 1987 Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):180-4.
15. Bosso 1989 Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. American Journal of Medicine 1989;87(Suppl 5a):123s-7s.
16. Cipolli 2001 Cipolli M, Cazzola G, Novelli A, Cassetta MI, Fallani S, Mazzeri T. Azithromycin concentrations in serum bronchial secretions of patients with cystic fibrosis. Clinical Drug Investigation 2001;21(5):353-60.
17. Davies 1987 Davies RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915-9.
18. Denning 1977 Denning CR, Park S, Grece CA, Mellin GW. Continuous vs intermittent oral antibiotics in the management of patients with cystic fibrosis [abstract]. Proceedings of the 18th Annual Meeting Cystic Fibrosis Club Abstracts; 1977. 1977:23.
19. Equi 2002 *Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360(9338):978-84.
20. Equi A, Bush A, Alton EW, Balfour-Lynn I, Rosenthsal M. A prospective double-blind randomised placebo controlled crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology 2001;Suppl 22:307.
21. Equi A, Bush A, Balfour-Lynn IM, Rosenthsal M. A prospective double-blind randomised placebo controlled crossover trial of azithromycin in paediatric cystic fibrosis [abstract]. Thorax 2002;57(Suppl iii):38.
22. Goldfarb 1986 Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, et al. Single dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986;26:222-6.
23. Harrison 1985 Harrison CJ, Marks MI, Welch DF, Sharma BB, Baker D, Dice J, et al. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to youg children with cystic fibrosis. Pediatric Pharmacology 1985;5(1):7-16.
24. Johansen 1999 Johansen HK, Børch K, Espersen F, Koch C, Høiby N. Pivmecillinam + pivampicillin vs. pivampicillin in cystic fibrosis patients with Haemophilus influenzae infection [abstract]. Proceedings of 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:89.
25. *Johansen HK, Børch K, Espersen F, Koch C, Høiby N. Randomised trial of pivampicillin plus pivmecillinam vs. pivampicillin in children and youg adults with chronic obstructive pulmonary disease and infection with Haemophilus influenzae. Current Medical Research and Opinion 1999;15(4):300-9.
26. Kapranov 1995 Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19.
27. Knight 1979 Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with Pseudomonas in their sputum. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:52.
28. Loening-Baucke 1979 *Loening-Baucke V, Mischler EH, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979;95(4):630-7.
29. Loening-Baucke V, Mischler EH, Myers MG. Cephalexin compared to placebo in the management of patients with cystic fibrosis [abstract]. Cystic Fibrosis Club Abstracts. 1978:69.
30. Loening-Baucke V, Mischler EH, Myers MG. Cephalexin in cystic fibrosis: a placebo-controlled study [abstract]. Pediatric Research 1978;12(4 Pt 2):495.
31. Mack 1991 Mack G, Cooper PJ, Buchannan N. Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1991;35(7):1484-5.
32. Nolan 1982 Nolan G, McIvor P, Levison H, Fleming PC, Corey M, Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. Journal of Pediatrics 1982;101(4): 626-30.
33. Ordonez 2001a Ordonex CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis. Pediatric Pulmonology 2001;32(1):29-37.
34. Owen 1991 Owen G, West J, Macguire S, Riley H, Goodchild M, Weller P. Continuous and intermittent antibiotic therapy in CF patients to age four years [abstract]. Proceedings of 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:95.
35. West J, Smith AW, Brown MRW, Weller PH. The longitudinal relationship between clinical status lung infection and immune responses in young cystic fibrosis patients [abstract]. Pediatric Pulmonology 1990;Suppl 5:222.
36. Williams J, Alfaham M, Riley HC, Goodchild MC, Weller PH, Dodge JA. Screening for cystic fibrosis in Wales and the West Midlands. 2: Clinical Evaluation [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:G(b)3.
37. Pirzada 1999 Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]. Pedaitric Pulmonology 1999;28(Suppl 19):263.
38. Postnikov 2001a Postnikov SS, Semykin SJ, Najimov VP. Safety of fluroquinolones in children [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001:P213.
39. Pukhalsky 2001 Pukhalsky AL, Shmarina GV, Kapranov NI, Kashirskaja NJ, Kokarovtseva SN, Shabalova LA, et al. Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;Suppl 22:274.
40. Saiman 2003 Nguyen D, Mayor-Hamblett N, Marshall BC, Saiman L, Burns JL. Phenotypic characterization of Pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):286.
41. Saiman L. What have we learned from further analysis of the U.S. macrolide trial? Subgroup analysis of azithromycin trial. Pediatric Pulmonology 2003;Suppl 25:165-7.
42. *Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56.
43. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2005;172(8):1008-12.
44. Scully 1987 Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC. Ciprofloxacin therapy in cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):196-201.
45. Shapera 1981 Shapera RM, Warwick WJ, Matsen JM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 1981;99(4):647-50.
46. Smith 1997 Smith A, Weber A, Pandher R, Williams-Warren J, Cohen ML, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106-8.
47. Sriram 2003 Sriram S, Young J, Waterhouse JC, Bucknall CE, Stack BHR. The antiinflammatory effect of clarithromycin in CF [abstract]. Journal of Cystic Fibrosis 2003;2(Suppl 1):S52.
48. Strandvik 1989 Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 1992;36(11):2512-7.
49. *Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson-Ehle I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scandinavian Journal of Infectious Diseases. Supplementum 1989;60:84-8.
50. Stutman 1987 Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):189-95.
51. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC. Pharmacokinetics of two doses regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):142-5.
52. Vitti 1975 Vitti TG, Berg TJ, Pagtakhan BS, Pagtakhan RD. The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis [abstract]. Proceedings of the 16th Annual Meeting Cystic Fibrosis Club Abstracts; 1975. 1975:56.
53. Weaver 1994 Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Archives of Disease in Childhood 1994;71(2):133-7.
54. Weaver LT, Green MR, Nicholson K, Heeley ME, Mills J, Kuzemko JA. Continuous prophylactic flucloxacillin improves outcome of infants with cystic fibrosis (CF) detected soon after birth [abstract]. Proceedings of 63rd Annual Meeting of the British Paediatric Association; Warwick, UK; 1991. 1991:24.
55. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Archives of Disease in Childhood 1994;70(2):84-9.
56. Wolter 2002 Bell SC, Seeney S, Walmsley K, Wolter JM, Bowler SD, McCormack JG. Long term treatment with azithromycin results in reduced exvivo inflammatory cytokine production in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 2002;Suppl 24:289-90.
57. Bowler SD. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics 2003;56(Suppl A):38.
58. Bowler SD, Masel PJ, Bell SC, Seeney SL, Wolter JM, McCormack JG. A prospective randomised trial of long termazithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology. 2000; Vol. Suppl 20:280.
59. Bowler SD, Seeney S, Walmsley K, Wolter JM, Bell SC, McCormack JG. Long-term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis [abstract]. Respirology 2002;7(Suppl):A9.
60. Seeney SL, Bowler SD, Wolter JM, Bell SC, Masel PJ, McCormack JG. A prospective randomised trial of long termazithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Internal Medicine Journal 2001;31(Suppl):A12.
61. * Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57(3):212-6.
62. Black 1991 Black A, Redmond A, Scott E. Randomised study comparing courses or oral ciprofloxacin alone with intermittent courses of intravenous azlocillin plus tobramycin or oral ciprofloxacin in the treatment of acute exacerbations of respiratory infection in cystic fibrosis [abstract]. Proceedings of the 16th Annual Meeting of the European Working Group for Cystic Fibrosis; 1989; Prague, Czechoslovakia. 1989:31.
63. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. Journal of antimicrobial chemotherapy 1990;26(Suppl F):25-9.
64. * Black A, Stevenson M, Scott E, Redmond A. Randomised study comparing oral ciprofloxacin alone with ciprofloxacin alternating with intravenous therapy in cystic fibrosis [abstract]. Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark. 1991:80.
65. Kurz 1987 * Kurz CC, Marget W, Harms K, Bertele RM. A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally [Kreuzstudie über die Wirksamkeit von Ofloxacin und Cirpofolxacin bei oraler Anwendung]. Infection 1986;14(Suppl 1):S82-S86.
66. Kurz CC, Marget W, Harms K, Bertele RM. Comparison of ciprofloxacin and ofloxacin in cystic fibrosis: a cross-over study [Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin im Kreuzversuch bei zystischer Fibrose]. Fortschritte der Antimikrobiellen u. Antineoplastischen Chemotherapie 1987;6:2107-13.
67. Postnikov 2001b Postnikov SS, Yu S, Semykin V, Nazhimov P, Kapranov NI. Comparative growth rate of a year at the children with mucoviscidosis treated and not treated with Ciprofloxacin: clinicomorphological comparisons. Antibiotiki I Khimioterapiia 2001;46(10):11-3.
68. Romano 1991 Romano L, Girosi D, Spallone E, Parisi F, Minicucci L, Romano C. The use of ofloxacin in cystic fibrosis patients [Uso dell'ofloxacin nei pazienti con fibrosi cistica]. Minerva Pediatrica 1992;44(3):79-86.
69. *Romano L, Minicucci L, Spallone E, Girosi D, Campelli A, Fabbri A, et al. Role of home therapy with ofloxacin in patients with cystic fibrosis (CF) [Ruolo della terapia domiciliare conofloxacin in pazienti con fibrosi cistica]. Giornale italiano di chemioterapia 1991;38(1-3):181-3.
70. Rubio 1987 Rubio TT. Ciprofloxacin: comparative data in cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4a):185-8.
71. Asensio 2000 Asensio O, Bosque M, Marco T, DeGracia J, Serra C. Home intravenous antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database of Systematic Reviews 2000, Issue 4.Art. No.: CD001917. DOI:10.1002/14651858.CD001917.
72. Ball 1986 Ball P. Ciprofloxacin: an overview of adverse experiences. Journal of Antimicrobial Chemotherapy 1986;18(Suppl D):187-93.
73. Ball 1990 Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. Journal of Antimicrobial Chemotherapy 1990;26(Suppl F):165-79.
74. Burns 2001 Burns JL, Gibson R, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases 2001;183(3):444-52.
75. CF Trust 2004 UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in people with cystic fibrosis: Suggestions for prevention and infection control. Report of the UK Cystic Fibrosis Infection Control Group 2004.
76. Döring 2000 Döring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
77. Elbourne 2002 Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
78. FitzSimmons 1993 FitzSimmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993;122(1):1-9.
79. FitzSimmons 1996 FitzSimmons SC. The Cystic Fibrosis Foundation Patient Registry Report 1996. Pediatric Pulmonology 1996;21(Suppl) :267-75.
80. Gibson 2003 Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
81. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
82. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic Reviews in Health Care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
83. Kosorok 2001 Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology 2001;32(4):277-87.
84. Nixon 2001 Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics 2001;138(5): 699-704.
85. Parad 1999 Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infection & Immunity 1999;67(9):4744-50.
86. Patterson 1991 Patterson DR. Quinolone toxicity: methods of assessment. American Journal of Medicine 1991;91(6A):35S-37S.
87. Rajan 2002 Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Seminars in Respiratory Infections 2002;17(1):47-56.
88. Ratjen 2006 Ratjen F. Diagnosing and managing infection in CF. Paediatric Respiratory Review 2006;7(Suppl 1):S151-3.
89. Rosenfeld 2001 Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology 2001;32(5):356-66.
90. Southern 2004 Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis (Coahrane Review). Cochrane Database of Systematic Reviews 2004, Issue 2.
91. Wang 2001 Wang S, Fitzsimmons S, O'Leary L, Rock M, Gwinn M, Khoury M. Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa in the first 10 years of life: a registry-based longitudinal study. Pediatrics 2001;107(2):274-9.
92. West 2002 West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al.Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287(22):2958-67.
93. Wood 2007 Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Cochrane Review). Cochrane Database of Systematic Reviews 2007, Issue 1.Art.No.: CD004197. DOI:10.1002/14651858.CD004197.pub2.